‘Transformative transaction’ for Roivant gives Roche rights to promising inflammatory bowel disease treatment
Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billion. Roivant owns 75% of Telavant shares, and Pfizer owns the remaining 25%.
The agreement, which includes a $7.1 billion upfront payment and a $150 million near-term milestone payment, also gives Roche an option to collaborate globally with Pfizer on a next-generation antibody that is currently in phase 1 trials, Roche said. Roivant shares gained 8% premarket on Monday, while Pfizer shares gained 1%. Roche’s American depositary receipts were down 0.5% premarket.
Roivant stock soared in late June after the company released data on RVT-3101 in adults with ulcerative colitis, showing the treatment resulted in improved clinical remission of 36% at week 56, versus 29% at week 14.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln DealBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it...
Read more »
Roche to Buy Telavant from Roivant Sciences, Pfizer for $7.1 BillionIt will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.
Read more »
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Bln -- UpdateBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss...
Read more »
Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 BillionSwiss pharmaceutical giant seeks to bolster pipeline
Read more »
Stock movers: Hess, Chevron, Roivant Sciences, Harpoon TherapeuticsHess Corp. Harpoon Therapeutics, Chevron, Pfizer, Roivant Sciences and Great Ajax were on the move.
Read more »
Chevron, Hess, Roivant, Textainer, Microsoft, Alphabet, and More Stock Market MoversChevron will buy Hess in all-stock deal valued at $53 billion, Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease...
Read more »